Michiyoshi Taga

ORCID: 0000-0002-5791-2348 · 4 papers in corpus
nonrandomized-trial 1998
The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem.83.2.4565

To evaluate the clinical utility of recently developed biochemical markers in the assessment of bone metabolism during GnRH agonist (GnRHa) treatment, we compared five bone resorption markers [C-telopeptide (CTX) and N-telopeptide (NTX) of …

observational 1997
Prolactin secretion in endometriotic patients
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/s0301-2115(96)02649-8

OBJECTIVE: To clarify a significance of prolactin (PRL) for infertility in endometriosis. STUDY DESIGNS: For seventy endometriotic patients with or without infertility, serum PRL concentrations measured by radioimmunoassay before and 30 mi…

nonrandomized-trial 1996
Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
Acta obstetricia et gynecologica Scandinavica ·doi:10.3109/00016349609033310

STUDY OBJECTIVE: To determine the reversibility of bone mineral density after the cessation of GnRH agonist treatment for endometriosis. DESIGN: Longitudinal trial with 6-month treatment period and 6-month follow-up. PATIENTS: 28 Japanese…

1986
31. Effects of Danazol, Buserelin or Gestrinone on Plasma Lipid and Lipoprotein Levels in Women with Endometriosis :